Drug intelligence / Profile preview

CO-End80B

Development stage: Preclinical
Lead developer: COBIK
Modality: Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems

Overview

CO-End80B is a recombinant bacteriophage-derived endolysin being developed by COBIK, in collaboration with its spin-off Sferogen, as an alternative antimicrobial therapy. It is designed to enzymatically degrade the bacterial cell wall and lyse *Staphylococcus* species, primarily targeting *Staphylococcus epidermidis* to treat bloodstream and medical device-related infections. The endolysin is also being formulated as a protein nanoparticle using Sferogen's proprietary platform to enhance its therapeutic potential.

Targets

PGN (Peptidoglycan)

Beyond the preview

Go deeper on CO-End80B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CO-End80B.